Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Protein Could Deliver Next Gene-Editing Tool

By Kenny Walter | February 6, 2019

A new gene-editing protein, CasX, may give CRISPR-Cas9 a run for its money. UC Berkeley scientists have determined the unique structure of CasX (grey), revealing that this pint-sized Cas enzyme is dominated by RNA (red) that directs it to specific sequences of DNA (blue), where it binds and cuts the DNA. Credit: University of California – Berkeley

While CRISPR Cas9 remains a mainstay in the genomics world, researchers have now found a much smaller protein called CasX that could be used for gene editing.

In 2017, a research team from the University of California Berkeley discovered in some of the world’s smallest bacteria a protein similar to Cas9 but substantially smaller, which could enable researchers to deliver a gene editor for both bacteria and human cells.

According to the study, the RNA-guided CRISPR-associated (Cas) proteins Cas9 and Cas12a provide adaptive immunity against invading nucleic acids, and function as powerful tools for genome editing in a wide range of organisms.

CasX is similar to both Cas9 and Cas12 in a number of ways, but different enough to where the researchers believe it evolved in bacteria independent of other Cas proteins. CasX can cut double-stranded DNA, much like Cas9, while also binding to DNA to regulate genes and can be targeted to specific DNA sequences similar to other Cas proteins.

Despite originating in bacteria that is not found in humans, the researchers combed through a database of microbes found in groundwater and sediment and discovered that the human immune system should accept CasX more easily than Cas9, as some doctors believe that Cas9 can create an immune reaction in patients treated with CRISPR therapies.

“The immunogenicity, delivery and specificity of a genome-editing tool are all vitally important,” co-lead author Benjamin Oakes, a former UC Berkeley graduate student and current Entrepreneurial Fellow in the Innovative Genomics Institute (IGI), said in a statement. “We’re excited about CasX on all of these fronts.”

The researchers used a cryo-electron microscope to capture snapshots of the CasX protein going through the motions of editing a gene. Here, they found more details on CasX’s molecular makeup and shape, proving that the protein evolved independently of Cas9 and shares no common ancestry.

“The first thing that jumps out is how the highly unique domains accomplish similar roles to what we have seen with other RNA-guided DNA-binding proteins,” Oakes said. “CasX’s minimal size, with no fat on the bone, helps to clearly demonstrate there is a basic recipe that nature uses. Understanding this recipe will help us to better evolve and engineer genome editing tools for our purposes rather than nature’s.”

The researchers will now work to further develop the next gene-editing tool.

“The culmination of biochemistry, genome editing and structure experiments within this single study is a prime example of the comprehensive efforts that are underway at the IGI,” Jennifer Doudna, IGI’s executive director, a UC Berkeley professor of molecular and cell biology and of chemistry and a Howard Hughes Medical Institute Investigator, said in a statement. “We aren’t just looking to uncover the next pair of molecular scissors. We want to build the next Swiss Army knife.”

The study was published in Nature.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE